Member Info for Willysang

The Expected Slot (This Week): Friday, June 5, 2026. If the regulators push the certificate out immediately upon signing to clear their desks.

​The Absolute Legal Limit: Friday, June 19, 2026. If they sign it this Friday but take the full, legally allowed 10 working days to process the digital code through the system infrastructure.

Primary Target: Friday, June 5, 2026 (Next Week)

​This marks exactly 20 working days from the moment the file left the technical evaluation center and landed on the ministerial desks in early May. Under Article 25 of the SAMR guidelines, this represents the standard legal limit for senior leadership to apply the official signature.

​Final Fallback: Friday, June 12, 2026

​Accounts for the final 10 working days legally permitted for the system infrastructure to generate the electronic certificate and mail out the physical "Blue Hat" licensing package.

The Primary Target: Friday, May 29, 2026 (This Week)

​This is the designated "Month-End Clean-Out" window. SAMR departments systematically execute automated digital server batch pushes on the final Friday of the month to hit internal processing quotas.

​The Secondary Target: Friday, June 5, 2026

​Marks exactly 20 working days from the moment the file left the technical evaluation floor and officially hit the ministerial signature desks.

​The Outlier: Friday, June 12, 2026

​The legal maximum limit allowing for final system generation and electronic delivery.

Target Date 1: Friday, May 22, 2026 (Tonight / Tomorrow Morning)

​The Probability: High (~65%)

​The Logic: By-Health's submission was formally processed into the system around late April. In China’s administrative framework, a file marked "In the Approval Stage" (审批中) typically faces a maximum 30-day statutory countdown for final ministerial signatures and electronic delivery. May 22 sits right at the expiration of that standard monthly cycle.

If an institutional holder wanted to completely dump and panic-sell 16+ million shares into the open market, the share price would have collapsed down toward the 0.50p mark. Instead, a buyer was lined up to take the entire chunk right at the current market value (1.00p–1.025p). This essentially acts as a psychological "floor"—it shows that large entities value the stock right where it is currently trading.

2 more weeks.....22nd May....29th May....we should have news by then👊

Maybe Trump will announce it 🥳

Scenario Chance Timeline

Approval this week 65% Friday, May 15th (matching the new law).

Approval late May 25% May 22nd or 29th (standard Friday batch releases).

Delayed to June 10% Only if the SAMR finds a technicality in the May 15th law transition.

As of May 12, 2026, we have fresh movement from By-Health. They broke their silence just as the Chinese government returned from the Labor Day holiday.

​Here is the "state of the union" for Qingluosu (轻络素):

​1. The May 7th Confirmation

​On May 7, 2026, By-Health provided a formal update on the investor interaction platform. The company officially stated:

​“The application for the new function declaration and product registration related to Qingluosu has been submitted and is currently in the approval stage.”

(“公司已递交轻络素相关的新功能申报及产品注册申请，目前尚在审批中。”)

​Why this is huge: This confirms that the "supplementary materials" (the homework the government asked for in April) were received and accepted into the final review queue. The company has done everything it can; the ball is 100% in the SAMR’s court now.

The "Most Likely" Dates

​Best Case: May 8, 2026 (Friday)

​Most Likely: May 15, 2026 (Friday)

​Why Fridays? The SAMR (State Administration for Market Regulation) typically releases batches of approved certificates and updates their "Mailing List" on Friday afternoons.

​📊 Why the next 14–21 days are critical:

​The "Homework" is Done: As of your April 22nd update, By-Health confirmed that the supplementary materials have been submitted. The technical review was already mostly complete; this last step is usually a 15–30 day administrative "lap."

​The May 15th Law: A major update to the Drug Administration Law takes effect on May 15, 2026. This law clarifies how products like Qingluosu move between "medical" and "health food" categories. It is highly probable the regulator is holding the final "stamp" to align with this new legal start date.

​Registration No. G20230087: As noted in the Eastmoney analysis from earlier today, this specific product (Xinluosu Tablets) has already passed field inspections. It is currently in the "Certificate Preparation" stage—meaning the "Yes" has likely already happened internally, and they are just waiting for the next batch release.

​🚩 What to watch for this week:

​No News is Good News: If there is no rejection by April 30th, it means the April 22nd submission was accepted without issue.

​The "Silent" Window: Expect silence until the second week of May. Chinese government offices will be on a break for the Labor Day holiday (May 1–5), so nothing will happen next week.

​The Verdict: You won't get an answer this week because of the upcoming holiday. Mark May 15th on your calendar as the "D-Day." If it doesn't drop then, the backup date is May 22nd. We are at the very end of a multi-year journey.

Because the materials were submitted by April 22nd, the timeline moves forward significantly:

​The Review Cycle: Once supplementary materials are submitted, the final review stage usually takes 15 to 30 business days.

​Target Window: This puts the final decision right in the middle of May 2026.

​May 15th Context: As mentioned before, the new Drug Administration Law implementation on May 15th remains a key date. The fact that By-Health rushed the submission before this date suggests they are trying to sync the approval with the new regulatory framework.

May 15th Milestone: A major update to the Drug Administration Law takes effect on May 15. This law clarifies the boundary between "medicine" and "health food." It is highly probable that the SAMR is waiting for this date to pass before officially stamping By-Health's Qingluosu certificate to ensure it aligns with the brand-new legal language.

This announcement confirms what long-term holders already know: Provexis is a perpetual pre-commercial story. DSM's stake is shrinking percentage-wise due to dilution, not growing conviction

What This Means (Straight Talk)

This is not final approval yet.

It means SAMR has reviewed the file and requested additional materials/documents (补正 / supplementation). This is very common in the final stages of new-function blue hat approvals, especially for first-of-its-kind claims like this one (platelet aggregation maintenance).

Positive side: The application is still alive and active. They wouldn’t be supplementing materials if it had been rejected.

Negative side: It introduces a new delay. The company now has to prepare and submit the extra info, after which SAMR will review it again (this step can take 2–8 weeks depending on complexity and backlog).

This explains the long silence since February 28. They were likely waiting for (or responding to) this supplementation request.

Updated Timeline Outlook

Most likely now: Late April to mid-May 2026 for final blue hat issuance (after they submit the materials and SAMR completes the review).

Best case: Mid-to-late April (if the supplementation is minor and fast-tracked).

Realistic base: May 2026.

Worst case: June or later (if more rounds of supplements are needed).

Most likely: Late March to mid-April 2026 (next 1–3 weeks from today). The next periodic batch or mailing list is the highest-probability trigger.

Updated Timeline (Realistic as of March 25)

Most likely: Late March – mid-April 2026 (next 1–3 weeks).

Best case: This week or next (sudden batch/mailing drop).

Realistic base: Early-to-mid April.

Worst case: Late April/May (further queuing for novel claims).

Blue cap...last batch was end of January...good chance next week 🙏

1 week closer....could drop Monday ✌️

Its losing steam ...but the blue cap could drop any day now ...

It's maximum 5/6 weeks...it's going to be massive..end of May ..worst case scenario....